The Multidisciplinary Pancreatic Cyst Program is designed to evaluate patients with known or suspected pancreatic cysts. The clinic is committed to a comprehensive one week evaluation incorporating all the resources available for the education, diagnosis, treatment and research of pancreatic cancer.
Lindsey L. Manos, MPAS, PA-C
Lindsey L. Manos is a Physician Assistant with the Department of Surgery at The Johns Hopkins Hospital. Lindsey is the Clinical Coordinator of The Johns Hopkins Multidisciplinary Pancreatic Cyst Program. Lindsey obtained her Masters Degree in Physician Assistant Sciences from Gannon University in 2009. Lindsey completed her clinical training at The University of Pittsburgh Medical Center and The Johns Hopkins Hospital in 2009. Lindsey is certified by the National Commission on Certification of Physician Assistants.
Anne Marie Lennon, MD, PhD (PubMed)
Dr. Anne Marie Lennon is an Associate Professor of Gastroenterology at The Johns Hopkins University School of Medicine in Baltimore, Maryland USA. She is the founder and Director of the Multidisciplinary Pancreatic Cyst Clinic at Johns Hopkins University. After receiving a medical degree from the Royal College of Surgeons in Ireland, and a PhD from University College Dublin, Dr. Lennon continued her residency training in internal medicine at the Mater Hospital, Dublin and the Cleveland Clinic, Cleveland, Ohio. She then completed a Fellowship in Gastroenterology in Edinburgh, United Kingdom, followed by a two year Advanced Endoscopy Fellowship in endoscopic ultrasound and ERCP at Johns Hopkins. She joined the faculty at Johns Hopkins in 2010. Dr. Lennon specializes in caring for patients with pre-cancerous lesions of the pancreas or pancreatic cancer.
Dr. Lennon is accredited in General Internal Medicine and Gastroenterology certified by the Joint Royal Colleges of Physicians Training Board (JRCPTB) of the United Kingdom. She is a Fellow of the American Society of Gastrointestinal Endoscopy and a Fellow of the Royal College of Physicians of Ireland. She has authored over 70 peer-reviewed papers, 21 book chapters and is the co-editor of the textbook Gastrointestinal Endoscopy in Practice. She has given multiple talks at national and international meetings on the management of patients with pancreatic cysts. Dr. Lennon's research is centered on developing better tools, and improving care for patients with pancreatic cysts.
Ashley Salamone, MSN, CRNP
Ashley Salamone is a nurse practitioner with the Department of Medicine at The Johns Hopkins Hospital, and is a former Johns Hopkins surgical intensive care (SICU) nurse. Ashley obtained her Masters' Degree in Nursing from The Johns Hopkins University in 2011 and completed her training at the Johns Hopkins Hospital and surrounding Baltimore institutions. Ashley is certified by the American Academy of Nurse Practitioners.
Christopher L. Wolfgang, MD, PhD (PubMed)
Dr. Christopher L. Wolfgang is the Chief of Hepatobiliary and Pancreatic Surgery at the Johns Hopkins Hospital and Professor of Surgery, Pathology and Oncology at Johns Hopkins Univesrity School of Medicine. He also is the Paul K. Neumann Professor of Pancreatic Cancer Research and a member of the Miller-Coulson Academy of Clinical Excellence. Dr. Wolfgang specializes in the care of patients with pancreatic cancer and pancreatic cysts and is among the highest volume pancreatic surgeons in the country. He routinely performs complex pancreatic operations including the standard Whipple Operation, laparoscopic and robotic Whipple Operations and Whipple Operations requiring vascular resection and reconstructions. He has particular interest in caring for patients with cystic lesions of the pancreas and is considered one of the world's experts having published over 200 scientific articles related to pancreatic cysts, pancreatic cancer and pancreatic surgery. He is a member of the International Consensus Guideline Committee that produced the most widely used guidelines in caring for patients with a pancreatic cyst. In addition he runs a basic and translational science lab that is investigating the early genetic changes of IPMN - the type of cysts that can lead to pancreatic cancer. Dr. Wolfgang obtained his medical degree from Temple University School of Medicine and residency training in General Surgery at Penn State Milton S. Hershey Medical Center. In addition, Dr. Wolfgang obtained a PhD degree in Biochemistry, also from Temple University School of Medicine. Dr. Wolfgang has completed a research fellowship in surgical oncology from Penn State and a clinical fellowship in gastrointestinal surgery at Johns Hopkins.
Nita Ahuja, MD, FACS (PubMed)
Dr. Nita Ahuja is a Professor of Surgery, Oncology and Urology at the Johns Hopkins University School of Medicine and the Jack Handelsman Professor in Abdominal Surgery. Dr. Ahuja is a board-certified and fellowship-trained surgical oncologist who specializes in treatment of cancers of the gastrointestinal system including pancreas, stomach, colon and rectum as well as retroperitoneal sarcomas.
Dr. Ahuja received her medical school degree from Duke University followed by general surgery training at Johns Hopkins University. She then completed advanced fellowship training in surgical oncology at Johns Hopkins before joining the faculty at Johns Hopkins as a surgical oncologist in 2003. Dr. Ahuja is recognized internationally for her expertise in the management of complex gastrointestinal cancers. She has published extensively in both clinical and basic science journals and has written several books on management of cancer including the book Living with Pancreas Cancer for patients and their families.
Dr. Ahuja runs a highly productive research laboratory that is focused on development of biomarkers for early detection of cancers and developing novel therapies for cancer. Her laboratory has identified promising markers for early detection of pancreas cancer using blood samples. She is now investigating the role of biomarkers for identifying high risk pancreas cysts. She currently also has multiple ongoing national and international trials focused on novel cancer therapies.
Martin Makary, MD (PubMed)
Dr. Martin Makary is Professor of Surgery at Johns Hopkins and specializes in laparoscopic pancreas surgery and directs the Laparoscopic Pancreas Surgery Program at Johns Hopkins. Dr. Makary is the Mark Ravitch Chair in Gastrointestinal Surgery and an active researcher in both minimally-invasive surgery and health services research.
He completed his education at Bucknell College, Thomas Jefferson University, and Harvard University and his general surgery residency at Georgetown University. He then completed advanced training in pancreas surgery at Johns Hopkins before joining the faculty as a GI surgeon. His clinical interests include minimally-invasive surgery for abdominal tumors and the association of frailty and risk in older surgical patients. Dr. Makary speaks nationally on new technology in surgical care, quality and safety in medicine, and health policy.
Matthew J. Weiss, MD (PubMed)
Dr. Matthew J. Weiss is an Assistant Professor of Surgery at the Johns Hopkins University School of Medicine. He is board-certified in general surgery and dual fellowship-trained in both complex surgical oncology and hepatopancreatobiliary (liver, pancreas and bile ducts) surgery. He earned his medical degree from Jefferson Medical College and performed oncology research at the Children's Hospital of Philadelphia. He trained in general surgery at the Johns Hopkins Hospital and completed a research fellowship at the Massachusetts General Hospital in immunology. He completed clinical fellowships at Memorial Sloan-Kettering Cancer Center in both surgical oncology and hepatopancreatobiliary surgery. His clinical interests include both benign and malignant tumors of the pancreas, liver, bile ducts, and gallbladder. He performs minimally invasive (laparoscopic and robotic) pancreas and liver operations.
Jin He, MD, PhD
Dr. Jin He is an Assistant Professor of Surgery at the Johns Hopkins University School of Medicine. He is board-certified in general surgery and fellowship-trained in complex surgical oncology and hepatopancreatobiliary (liver, pancreas and bile ducts) surgery. He earned his medical degree from Beijing Medical University and performed postdoctoral oncology research at the UT Southwestern Medical Center. He was then trained in general surgery at the Johns Hopkins Hospital and completed clinical fellowships at the Johns Hopkins Hospital in both surgical oncology and hepatopancreatobiliary surgery. His clinical interests include both benign and malignant tumors of the stomach, liver, pancreas, bile ducts, and gallbladder. He performs minimally invasive (laparoscopic and robotic) pancreas and liver operations.
Mary Hodgin, RN
Mary Hodgin is a certified medical-surgical nurse with a wealth of experience, practicing at Johns Hopkins Hospital since 1977. She received her Bachelor of Science in Nursing Degree from University of Maryland in 2003, and her Masters in Nursing Informatics in 2008. Employing her background as a senior staff nurse, Mary brings her understanding of inpatient concerns to complement her role as a triage nurse and research coordinator in the pancreas cyst program.
There are multiple types of pancreatic cysts. The faculty of The Department of Pathology integrate the most advanced diagnostic technologies with translational research to provide cutting edge diagnostic excellence. We have extensive expertise in both Surgical Pathology (the interpretation of biopsies and surgically resected materials), and in Cytopathology (the interpretation of cells that are removed from tissues by fine needle aspiration).
Ralph H. Hruban, MD (PubMed)
Dr. Ralph H. Hruban is the Director of the Department of Pathology, and Professor of Pathology and Oncology at The Johns Hopkins University School of Medicine in Baltimore, Maryland USA. He also is the Director of the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins University.
After receiving an undergraduate degree from the University of Chicago and a medical degree from The Johns Hopkins University, Dr. Hruban continued his residency training in anatomic pathology at Johns Hopkins. He then completed a fellowship in surgical pathology at Memorial Sloan-Kettering Cancer Center in New York and returned to join the faculty at Johns Hopkins in 1990.
Dr. Hruban has authored over 600 peer-reviewed manuscripts and five books including the standard textbook on pancreatic pathology (the AFIP Fascicle on Tumors of the Pancreas) and the World Health Organization "blue book" on tumors of the digestive tract. He is recognized by the Institute for Scientific Information as a Highly Cited Researcher and by Essential Science Indicators as the most highly cited pancreatic cancer scientist. He was recently identified as a "highly influential" biomedical researcher (Euro.J.Clin.Invest.2013,43:1339-65). He helped create the Johns Hopkins Pancreatic Cancer website, an award-winning iPad application (app) to teach pancreas pathology, and an iPad and iPhone app for patients. Dr. Hruban has made these "apps" free to the pancreas community with the goal of i mproving the practice of pancreas pathology around the world. Dr. Hruban is a member of the Scientific Advisory Boards of The Joseph C. Monastra Foundation, The Michael Rolfe Pancreatic Cancer Foundation, and The Lustgarten Foundation.
Dr. Hruban has received a number of awards including the Arthur Purdy Stout Prize for significant career achievements in surgical pathology, the Ramzi Cotran Award from the United States and Canadian Academy of Pathology, the PanCAN Medical Visionary Award, the Ranice W. Crosby Distinguished Achievement Award in Art as Applied to Medicine, the Ruth C. Brufsky Award of Excellence in Clinical Research for Pancreatic Cancer, the Frank Netter Award for Special Contributions to Medical Education, the Johns Hopkins University Distinguished Alumni Award, the Team Science Award from the American Association for Cancer Research, the Ruth Leff Siegel Award for Pancreatic cancer Research, and five teaching awards from the Johns Hopkins School of Medicine. He was elected to the German National Academy of Sciences Leopoldina in 2013.
The goals of Dr. Hruban's research are to understand the noninvasive precursor lesions from which invasive pancreatic cancers develop (PanINs and IPMNs), why pancreatic cancer aggregates in some families, and the pathologic ramifications of genetic alterations in the pancreas. Towards these goals Dr. Hruban has applied molecular genetics to the study of noninvasive precursor lesions in the pancreas and to patients with familial pancreatic cancer. A better understanding of these lesions and families may provide an avenue for the early detection of pancreatic cancer.
Syed Ali, MD (PubMed)
Dr. Syed Ali serves as Professor of Pathology and Radiology at the Johns Hopkins University School of Medicine and The Johns Hopkins Hospital in Baltimore, Maryland, USA. He is also the Director of the Division of Cytopathology and Director of the Cytopathology fellowship training program. Dr. Ali did his Anatomic and Clinical Pathology residency at North Shore University Hospital-Cornell University Medical College in New York. This was followed by two fellowships; one in Oncologic Surgical Pathology at the Memorial Sloan-Kettering Cancer Center in New York and the other one in Clinical Cytopathology at The Johns Hopkins Hospital.
Dr. Ali has authored well over 170 peer-reviewed articles in major scientific journals, over 20 books/book chapters and electronic media. He travels widely and is a sought after speaker nationally and internationally. His major interest is focused on clinicopathologic analyses by attempting to address diagnostic issues and prognostic factors, primarily based on aspiration cytopathology of pancreas and thyroid. His latest work is the editorship of the highly acclaimed book on the new Thyroid Bethesda System, which has taken him to over 15 countries for well over 30 invited lectures in the last two years. The book has been translated into multiple languages. His expertise also includes illustrating the emerging role of high-resolution digital photo imaging, whole slide virtual microscopy and remote telepathology in education, research and routine diagnostic pathology. He has been instrumental in creating novel web-based tutorials, podcasts, and house staff performance evaluation tools to more sophisticated virtual photomicroscopy in diagnostic pathology. Dr. Ali serves on the editorial board of key scientific journals and has major appointments in several professional Pathology organizations including, membership of the executive board and chairmanship of the scientific program committee of the American Society of Cytopathology.
Elliot Fishman, MD (PubMed)
Dr. Elliot K. Fishman received his bachelor's degree in 1973 and his medical degree in 1977 from the University of Maryland. After a residency at Sinai Hospital in Baltimore, Dr. Fishman completed a Fellowship in Computed Tomography in 1980 at Johns Hopkins Hospital and joined The Russell H. Morgan Department of Radiology and Radiological Science at Johns Hopkins in 1981 as an Assistant Professor. In 1986, he became Associate Professor and, in 1991, Professor of Radiology and Oncology.
Dr. Fishman's clinical and research interests have focused on medical imaging with specific emphasis on 3-Dimensional Imaging and Computed Tomography. He was involved from the beginning in the development of 3D Imaging through his work with Pixar, which was a spin-off from LucasFilms in San Rafael, California. Over the last 25 years, Dr. Fishman continued to help develop 3D imaging and has been a leader in the development of interactive 3D rendering. Today, this is a major part of state-of-the-art imaging with a significant impact on patient care and management. Dr. Fishman's interests in computed tomography have spanned the era from early scanners that took 10 seconds per slice, to the scanners of today where the studies are done in less than 1 second. His research team is one of the world's leading groups in developing new techniques and technologies, whether in visualization or post-processing tools. Dr. Fishman's work in CT has spanned the past 30 years and has resulted in over 1000 peer-reviewed publications; he has also been the author or co-author of 8 textbooks. Dr. Fishman is a member of various organizations and is a past-president of the Society of Body CT/MR.
During his career at Hopkins, his involvement has included graduate and post-graduate education, teaching and, most importantly, patient care. In terms of education, Dr. Fishman has been a sought-after speaker worldwide for many Continuing Medical Education (CME) courses and has given many named lectures. He has coordinated more than 100 CME courses for Johns Hopkins School of Medicine, including the CT Cutting Edge Course for the past 25 years. Dr. Fishman has also developed one of the largest websites in medical imaging and surely the largest in CT, known as www.CTISUS.com. This website is currently used each month by over 50,000 medical professionals from more than 100 countries. The site has been honored by numerous organizations for its excellence and is one of the sites chosen sites for Medscape.
Dr. Fishman was recognized for his excellence in education and teaching when he received three Aunt Minnie Awards: as Outstanding Educator in 2002 and 2007, and as Outstanding Researcher in 2004. Radiologists throughout the world choose the recipients of the annual Aunt Minnie Awards and Dr. Fishman is the first person ever to receive both awards. In addition, in April of 2007, Medical Imaging named Dr. Fishman the "top radiologist" in the nation.
Atif Zaheer, MD (PubMed)
Dr. Atif Zaheer is an assistant professor in the Department of Radiology at the Johns Hopkins University. Dr. Zaheer attended medical school at the Aga Khan University. This was followed by a radiology residency at the Beth Israel Medical Center/Harvard Medical School in diagnostic radiology and a fellowship in abdominal imaging and intervention at the Brigham and Women's Hospital/Harvard Medical School.
As faculty at the Johns Hopkins University, Dr. Zaheer is actively involved in research and education and believes in a multidisciplinary approach for evaluation of disease. He is clinically active in cross-sectional imaging of the body using CT, MRI and Ultrasound. He is involved in the multidisciplinary conferences for liver, pancreas and prostate. His research interests include imaging of tumors and inflammatory disorders of the pancreas.
Bernadette Cullen, MBBCh, MD
Dr. Bernadette Cullen is an Assistant Professor of Psychiatry with the Department of Psychiatry and Behavioral Sciences at the School of Medicine and with the Department of Mental Health at the School of Public Health. She is the Director of the Johns Hopkins Community Psychiatry Out-patient Program. Dr. Cullen is a 1988 graduate of Trinity College Dublin. She completed her general practitioner and psychiatry residencies in St. James Hospital, Dublin and completed research and clinical fellowships at Johns Hopkins Medical Institutions. She joined the faculty at Johns Hopkins in 2001. Her research interests include: service delivery to those with mental health illnesses and obsessive compulsive disorder.
Bert Vogelstein, MD (PubMed)
Dr. Bert Vogelstein was the first to elucidate the molecular basis of a common human cancer. His work on colorectal cancers forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies in the future.
Vogelstein attended the University of Pennsylvania, where he graduated Summa Cum Laude with distinction in mathematics. He obtained his medical degree at the Johns Hopkins University School of Medicine and performed his residency in pediatrics at the Johns Hopkins Hospital. Following his clinical training, Dr. Vogelstein completed a post-doctoral fellowship at the National Cancer Institute, focusing on the development of new techniques in molecular biology. He returned to Johns Hopkins as an Assistant Professor in Oncology, and is now Clayton Professor of Oncology and Pathology. Dr. Vogelstein also holds a joint appointment in Molecular Biology and Genetics at JHU and is an Investigator of the Howard Hughes Medical Institute. He is currently the Director of the Ludwig Center for Cancer Genetics & Therapeutics at the Johns Hopkins Kimmel Cancer Center.
Kenneth Kinzler, PhD (PubMed)
Dr. Kenneth Kinzler is a Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center (SKCCC) at the Johns Hopkins University School of Medicine. According to the Institute for Scientific Information in Philadelphia, Dr. Kinzler is one of the most influential scientists alive today. He has produced classic studies of the genes causing human cancer including the discovery of APC, the gene that initiates virtually all colorectal tumors. His subsequent analyses of the functional properties of the APC gene product have had widespread ramifications for developmental biology as well as cancer biology. He is also internationally renowned for his development of genetic methods for analyzing gene expression and mutations in human cancer leading to his most recent work on defining the cancer genome for more than a dozen human tumor types. His work has spawned over 100 patent applications, most focused on the use of genetic approaches to improve the diagnosis and management of patients with cancers and other serious diseases.
Dr. Kinzler received his B.S. in Toxicology from the Philadelphia College of Pharmacy and Science, graduating Magna cum laude and obtaining the highest average in the toxicology curriculum. In 1988, he received a doctorate in Pharmacology and Molecular Sciences from the Johns Hopkins University School of Medicine, where he also completed a fellowship in oncology. In 1990, he joined the faculty of the SKCCC. Dr. Kinzler was promoted to Professor of Oncology in 1999 and is currently co-director of the Ludwig Center at Johns Hopkins University.
Among his many honors are the Philadelphia College of Pharmacy and Science Alumni Award, The Johns Hopkins University School of Medicine Sandoz Award for Superior Academic Achievement and Contribution to Health Care, the David Israel Macht Award for Excellence in Research and the Inaugural National Brain Tumor Society Founders Award. He's a recipient of a National Cancer Institute's Merit grant and an original member of the Institute for Scientific Information Highly Cited Researchers. He has served on the National Cancer Institute's Scientific Advisory Board and the American Association of Cancer Research's Board of Directors. He has coauthored over 300 peer-reviewed articles on the molecular analyses of cancer and what many consider to be the definitive book on human cancer genetics. Although Dr. Kinzler is only 49, he has ranked among the most influential scientists worldwide over the last 25 years. In summary, Dr Kinzler is a world recognized expert on the molecular and genetic analysis of human cancer who has been responsible for numerous advances in this field.
Nickolas Papadopoulos, PhD
Dr. Nickolas Papadopoulos is internationally known as a co-discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC), one of the most common hereditary forms of cancer. His discovery that mutations in the mismatch repair genes (MSH2, MLH1, MSH6, and PMS2) predispose to HNPCC had important ramifications for the understanding and molecular classification of cancers that have a very high rate of certain type of mutations. These discoveries lead to the development of diagnostic tests for the presymptomatic diagnosis of individuals with HNPCC, invaluable information for the management of the families with HNPCC. He is well renowned for his development of diagnostic tests and he is considered an expert in cancer diagnostics. He not only developed diagnostics at the bench, but as a Chief Scientific Officer of a startup diagnostics company he lead a team in the development and commercialization of a novel diagnostic method applicable to any gene tic disease. His current focus is on cancer genomics. He was part of the interdisciplinary team that was first to sequence all of the protein coding genes and determine genetic alterations and construct expression profiles in multiple tumors of four different common human cancers. Most recent efforts have involved the identification of genetic alterations that drive tumorigenesis using a new generation of sequencing technologies. A noteworthy discovery he has made in the recent year include the identification of novel, signature mutations in ovarian clear cell carcinomas and pancreatic neuroendocrine tumors. These mutations are in genes that control epigenetic changes in the cell, thus, developing the paradigm that epigenetic changes in cancer cells are controlled by genetic changes. This work has provided new insights into the pathogenesis of these tumor types as well as new diagnostic strategies. Currently, he is focused on translating the genetic information derived from c ancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer.
Michael Goggins, MD (PubMed)
Dr. Michael Goggins is a Professor of Pathology, Medicine and Oncology in the Divisions of Gastroenterology/ Hepatology and Gastrointestinal Pathology and an Attending Physician in the Department of Medicine, and is Director of the Pancreatic Cancer Early Detection Laboratory at the Sol Goldman Pancreatic Cancer Research Center at the Johns Hopkins Medical Institutions, Baltimore, MD, USA. Professor Goggins is a 1988 graduate of Trinity College Dublin. He did his internal medicine and gastroenterology training in St. James' hospital, Dublin and Johns Hopkins University. He was a Lecturer in Medicine at Trinity College from 1992-1995. He was a research fellow in cancer genetics at Johns Hopkins from 1995-1998 He joined the faculty at Johns Hopkins in 1998 and is Director of the Pancreatic Cancer Early Detection Laboratory. His research interests include the early detection of pancreatic neoplasia through molecular markers, pancreatic cancer screening, familial pancreatic cancer susceptibility gene discovery and identifying genetic and epigenetic alterations that predict response to therapy. He is the author of over 200 peer reviewed publications, holder of several patents and was recognized by Essential Science Index as the 6th most highly cited pancreatic cancer scientist in the decade between 1996-2006.
Laura D. Wood, MD, PhD (PubMed)
Dr. Laura Wood is an Assistant Professor in the Department of Pathology, Division of Gastrointestinal and Liver Pathology at the Johns Hopkins University School of Medicine. Dr. Wood received her B.S. in Biology from the College of William & Mary, graduating Summa Cum Laude with membership in Phi Beta Kappa. She then went on to earn both her M.D. and Ph.D. from The Johns Hopkins University School of Medicine, with membership in Alpha Omega Alpha. She completed her Ph.D. research in the laboratory of Dr. Bert Vogelstein, where she led the first whole exome sequencing studies in human cancers. Dr. Wood then went on to complete residency in Anatomic Pathology (serving as Chief Resident in her final year) and fellowship in Gastrointestinal and Liver Pathology at The Johns Hopkins Hospital. Now, she is leads her own basic science laboratory focused on genetic characterization of pancreatobiliary cancers and their precursor lesions.
Rachel Karchin, PhD (PubMed)
Dr. Rachel Karchin is an Associate Professor in the Department of Biomedical Engineering at Johns Hopkins University. She received a Ph.D. in Computer Science from the University of California, Santa Cruz in 2003, spent three years as a postdoctoral fellow in the Department of Biopharmaceutical Sciences at University of California, San Francisco, and joined the Hopkins faculty in 2006. Her lab develops algorithms and tools to interpret and model genomic data, with a focus on cancer. Dr. Karchin has a joint appointment in the Department of Oncology and a secondary appointment in the Department of Computer Science. She is currently the William R. Brody Faculty Scholar at Johns Hopkins Whiting School of Engineering.
David Mascia, PhD (PubMed)
Dr. David Masica is a computational biologist in the Dept. of Biomedical Engineering and the Institute for Computational Medicine. Part of his research focuses on the development of novel methods for predicting the influence of genetic alteration on human health and disease. From this work, he has isolated and published many new genetic markers of disease progression and so-called "actionable" targets, which are markers of drug response and therapeutic intervention. These genetic markers can help physicians more accurately diagnose the stage or type of a patients cancer using noninvasive techniques, as well as inform safe and effective treatment protocols. These approaches fall under the umbrella of "personalized medicine", where diagnosis and treatment are based on each patients uniquely individual genetic signatures.
Alison Klein, PhD, MHS
Associate Professor of Oncology, Pathology and Epidemiology, Dr. Alison Klein is a trained genetic epidemiologist/statistical geneticist specializing in pancreatic disorders, including pancreatic cancer and its risk factors. Dr. Klein has studied the genetic epidemiology of pancreatic cancer for over 15 years. She is Director of the National Familial Pancreas Tumor Registry, the largest registry of familial pancreatic cancer in the world. Currently over 4,500 families have enrolled in this registry including over 1,500 with familial pancreatic cancer (defined as a kindred with at least a pair of first-degree relatives with pancreatic cancer). Her long-term interests include understanding the genetic and environmental risk factors that cause GI disorders, and developing risk prediction models for diseases of the pancreas and GI cancers. Dr. Klein’s work has laid the foundation for much of our understanding of inherited basis of pancreatic cancer. In collaboration others at the Sol Goldman Pancreatic Cancer Research Center, she recently helped to lead the efforts that identified PALB2 and ATM as a causes of familial pancreatic cancer. Dr. Klein is PI of a NCI/CIDR supported multi-center GWAS for pancreatic cancer. She is co-leading the ongoing Familial Pancreatic Cancer Genome Sequencing Study. This ongoing collaborative study brings together families from over 10 familial pancreatic cancer registries with the goal of identifying pancreatic cancer predisposition genes through whole genome sequencing. In addition, Dr. Klein is also a member of the steering committee of the Pancreatic Cancer Case-Control Consortium.
Marco Dal Molin, MD
Dr. Marco Dal Molin is a post-doctoral research fellow in the Sol Goldman Pancreatic Cancer Research Center and serves as the Coordinator for a large multi-center international study on early detection of pancreatic cystic neoplasms (NCT02110498). His research focuses on the integration of clinical features and molecular tests for the differential diagnosis of pancreatic cysts. In addition, he is exploring the use of genetic tests for the early diagnosis of pancreatic cancer. He obtained his medical diploma at the University of Verona, School of Medicine in Italy, and completed a general surgery residency in the Department of Surgery – Pancreas Institute, also at the University of Verona.